Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Vij

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Cancer Immunology Research|November 7, 2025
Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunitySheela R Damle, Jason A Carter, Kristin E Goodsell, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Leukemia|August 31, 2013
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseV Bachanova, D I Marks, M-J Zhang, et al.
American Journal of Hematology|January 13, 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomesJames R Cerhan, Matthew J Maurer, Brian K Link, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Cancer Immunology Research|November 7, 2025
Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunitySheela R Damle, Jason A Carter, Kristin E Goodsell, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Leukemia|August 31, 2013
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseV Bachanova, D I Marks, M-J Zhang, et al.
American Journal of Hematology|January 13, 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomesJames R Cerhan, Matthew J Maurer, Brian K Link, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Pageof 6